)
Josh Schimmer, MD, MBA
Biotech Equity Research Analyst
Cantor Fitzgerald and Co.
Josh Schimmer is a biotech equity research analyst at Cantor Fitzgerald and Co. Dr. Schimmer, who has more than 15 years of biotechnology research experience, previously worked at Evercore ISI, Piper Jaffray, Lazard Capital Markets, Leerink Partners, and Cowen & Co. In addition, he spent two years on the buy-side at Davidson Kempner. Dr. Schimmer received his M.D. and subspeciality training in internal medicine and rheumatology from the University of Toronto and earned an MBA from Harvard Business School.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}